rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Joseph M. Limber

Director

Company insider

Files Form 4 as: Director, XOMA Royalty; Director, CombiMatrix; Director, Molecular Insight Pharmaceuticals; Director, Panacos Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
80
Buys
3
Sells
0
Bought
$760K
Sold
$0
Companies
4
Companies where not an officer
4
First trade
24 Jan 2006
Last trade
14 Jul 2026
Last filed
14 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
XOMA RoyaltyDirector · Biotechnology · last 14 Jul 20263 buys · 0 sells
CombiMatrixDirector · last 28 Feb 20120 buys · 0 sells
Molecular Insight PharmaceuticalsDirector · last 13 May 20100 buys · 0 sells
Panacos PharmaceuticalsDirector · last 19 Jun 20080 buys · 0 sells

Activity over time

1 Mar 2025 – 1 Oct 2026
02Mar 25Aug 25Jan 26May 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
14 Jul 2026filed 14 Jul 2026XOMA RoyaltyBiotechnologySEC FORM 4 Code J—9,532filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivative · BiotechnologySEC FORM 4 Code D—8,996 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivative · BiotechnologySEC FORM 4 Code D—10,967 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivative · BiotechnologySEC FORM 4 Code D—9,763 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivative · BiotechnologySEC FORM 4 Code D—9,936 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA RoyaltyBiotechnologySEC FORM 4 Code D—10,000filing
14 Jul 2026filed 14 Jul 2026XOMA RoyaltyBiotechnologySEC FORM 4 Code D—20,000filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—8,000 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—2,366 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—5,052 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—8,167 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—6,152 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—5,101 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—8,996 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—10,967 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—9,763 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivativeSEC FORM 4 Code D—9,936 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivative · BiotechnologySEC FORM 4 Code D—8,000 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivative · BiotechnologySEC FORM 4 Code D—2,366 at $0.00filing
14 Jul 2026filed 14 Jul 2026XOMA Royaltyoption or derivative · BiotechnologySEC FORM 4 Code D—5,052 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed3

Buys in green, sells in red, by the company’s sector.

Related people

BVF PARTNERS L P/ILDirector and Other role · 10% owner at XOMA Royalty, filing Form 4 there in the last year
Heather L. FranklinDirector · Director at XOMA Royalty, filing Form 4 there in the last year
Matthew D. PerryDirector · Director at XOMA Royalty, filing Form 4 there in the last year
Owen HughesChief Executive Officer · Chief Executive Officer at XOMA Royalty, filing Form 4 there in the last year
Barbara KosaczDirector · Director at XOMA Royalty, filing Form 4 there in the last year